Compare Nokia Corp (NOK) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Sana Biotechnology Inc — how do they compare? Nokia Corp trades at $10.8 (market cap $59.77B), while Sana Biotechnology Inc trades at $3.17 (market cap $1.03B). The key difference: Nokia Corp is far larger — about 58× Sana Biotechnology Inc's market cap, and Nokia Corp pays a 1.53% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NOK | SANA | |
|---|---|---|
Market Cap | $59.77B | $1.03B |
Sector | Technology | Health |
52-Week High | $16.83 | $5.92 |
52-Week Low | $4.51 | $2.68 |
Enterprise Value | $57.71B | $946.04M |
Dividend Yield | 1.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.66, up 6.18% today, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while revenue trends stabilize around $20B annually. The company maintains a solid balance sheet with $8.91B cash and reduced debt-to-asset ratio of 9.09 in 2025. Positive news includes AI-driven network expansion and Euro Stoxx 50 reinstatement, though cash flow volatility and competitive pressures persist.
Outlook: Growth is supported by AI infrastructure demand and portfolio diversification, but risks include execution challenges and margin pressures. With 61.5% analyst buy ratings and technical momentum, the stock offers upside potential, though investors should weigh high P/E of 76.42 against earnings consistency and free cash flow trends.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
